Regeneron presentations at ash highlight expanding clinical research in blood cancers and disorders

New data for regn5458 (bcmaxcd3 bispecific antibody) in patients with heavily pre-treated multiple myeloma to be highlighted in an oral presentation first data evaluating a combination therapy approach with pozelimab (c5 antibody) and alnylam's cemdisiran (sirna c5 inhibitor) in healthy volunteers regeneron will host an investor webcast on monday, december 13 to provide further updates across its hematology portfolio tarrytown, n.y., nov. 4, 2021 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that new and updated data from its diverse hematology program in blood cancers and disorders will be presented at the 2021 american society of hematology (ash) annual meeting from december 11-14 in atlanta, ga.
REGN Ratings Summary
REGN Quant Ranking